AbbVie (ABBV) Tops Q2 EPS by 4c, Raises FY Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
AbbVie (ABBV) climbs after raising full-year earnings guidance
July 27, 2023 9:09 AM EDTAbbVie (NYSE: ABBV) shares are climbing premarket on the back of its second-quarter profit and revenue beat. The company also raised earnings per share guidance.
The pharmaceutical firm reported Q2 EPS of $2.91, $0.04 better than the analyst estimate of $2.87. Revenue for the quarter... More
